Not a good look, but probably just a pleb/comp sec stuffing up their spreadsheet.
Whilst management haven't delivered us a take-over or a partnership, I don't think they've done a terrible job (..yet?). At the end of the day, AVX is cashed up, navigated the GFC, has had nothing but successful trial results (with hopefully one to come in late Jan/early Feb), a possible deal with Tibotec (currently out of AVX's hands from my understanding) and a potential partner for ATC after results (granted, I was hoping this would happen a while ago but for all we know the management deemed negotiations unsatisfactory and decided to end the trial early to maximise potential deals).
Yes their timing on CR's hasn't been great - but who can predict the SP? We were a lot higher when the company had a lot more risk so go figure.
Hmm, I may be completely wrong, but let's sit tight for results in next few weeks, the Tibotec announcement, then in a few months a partner deal. If the drug is as good as we think, someone will snap us up.
Finally, looks like the Biotech sector is heating up... good time for a few cracker announcements!!!
Good luck all.
AVX Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
